Laurion Capital Management LP Sells 20,000 Shares of Tricida Inc (TCDA)

Laurion Capital Management LP reduced its stake in shares of Tricida Inc (NASDAQ:TCDA) by 16.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 105,000 shares of the company’s stock after selling 20,000 shares during the quarter. Laurion Capital Management LP owned 0.25% of Tricida worth $3,208,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the company. Orbimed Advisors LLC bought a new position in shares of Tricida during the second quarter valued at about $325,589,000. Baker BROS. Advisors LP purchased a new stake in shares of Tricida during the second quarter worth about $47,840,000. FMR LLC purchased a new stake in shares of Tricida during the second quarter worth about $33,329,000. BlackRock Inc. boosted its holdings in shares of Tricida by 216.4% during the third quarter. BlackRock Inc. now owns 1,005,103 shares of the company’s stock worth $30,707,000 after purchasing an additional 687,414 shares during the period. Finally, Vivo Capital LLC purchased a new stake in shares of Tricida during the second quarter worth about $29,652,000. 68.39% of the stock is currently owned by hedge funds and other institutional investors.

Tricida stock opened at $29.87 on Friday. The company has a quick ratio of 12.68, a current ratio of 12.68 and a debt-to-equity ratio of 0.11. Tricida Inc has a 1-year low of $21.87 and a 1-year high of $40.10.

Tricida (NASDAQ:TCDA) last posted its earnings results on Thursday, November 8th. The company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.84) by $0.19. As a group, equities research analysts forecast that Tricida Inc will post -2.92 EPS for the current year.

In other news, insider Geoffrey M. Parker bought 5,000 shares of the company’s stock in a transaction dated Tuesday, November 13th. The stock was bought at an average cost of $29.72 per share, for a total transaction of $148,600.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

A number of research firms have recently weighed in on TCDA. Zacks Investment Research lowered shares of Tricida from a “buy” rating to a “hold” rating in a report on Wednesday, September 26th. Cowen reiterated a “buy” rating on shares of Tricida in a report on Friday, November 9th.

TRADEMARK VIOLATION NOTICE: “Laurion Capital Management LP Sells 20,000 Shares of Tricida Inc (TCDA)” was published by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at

Tricida Profile

Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer drug that has completed Phase III clinical trials to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is headquartered in South San Francisco, California.

See Also: Do Tariffs Work?

Want to see what other hedge funds are holding TCDA? Visit to get the latest 13F filings and insider trades for Tricida Inc (NASDAQ:TCDA).

Institutional Ownership by Quarter for Tricida (NASDAQ:TCDA)

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with's FREE daily email newsletter.

Leave a Reply